A PHASE 1, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN PATIENTS WITH IRON OVERLOAD
		        
		        	EHA Library, Vip Viprakasit, 
		        			                214475
		            		       
		    
				
			
		        PANOBINOSTAT, DECITABINE, AND DONOR LYMPHOCYTE INFUSION POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE HOVON 116 STUDY IN NEWLY DIAGNOSED POOR-RISK AML PATIENTS
		        
		        	EHA Library, Jan Cornelissen, 
		        			                214550
		            		       
		    
				
			
		        MOR202 WITH LOW-DOSE DEXAMETHASONE (DEX) OR POMALIDOMIDE/DEX OR LENALIDOMIDE/DEX IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE I/IIA, MULTICENTER, DOSE-ESCALATION STUDY
		        
		        	EHA Library, Marc Raab, 
		        			                214462
		            		       
		    
				
			
		        OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW‐DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
		        
		        	EHA Library, Paul Richardson, 
		        			                214461